Document Detail


Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
MedLine Citation:
PMID:  19755414     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study is to determine whether the inhibition of CYP2D6 and CYP3A4 enzyme activity with telithromycin affects the pharmacokinetics and pharmacodynamics of orally administered oxycodone in a randomized 2-phase crossover study. Eleven healthy subjects were pretreated with 800 mg of oral telithromycin or placebo for 4 days. On day 3, they ingested 10 mg of immediate-release oxycodone. Plasma concentrations of oxycodone and its oxidative metabolites were measured for 48 hours, and pharmacodynamic effects were evaluated. Telithromycin increased the area under the plasma concentration-time curve (AUC(0-infinity)) of oxycodone by 80% (P < .001) and reduced the AUC(0-infinity) of noroxycodone by 46% (P < .001). Most of the pharmacokinetic changes were seen in the elimination phase, with little effect by telithromycin on the peak concentration of oxycodone. Pharmacodynamic effects of oxycodone were modestly enhanced by telithromycin. In conclusion, telithromycin clearly reduces the N-demethylation of oxycodone to noroxycodone by inhibiting the CYP450 3A4 enzyme. The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects. Reduction of oxycodone dose by 25% to 50% followed by readjustment according to the clinical response might be appropriate.
Authors:
Juha Gr?nlund; Teijo Saari; Nora Hagelberg; Ilkka K Martikainen; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Related Documents :
20599794 - Pharmacokinetics of opda, an organophosphorus hydrolase, in the african green monkey.
3144534 - Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
6839614 - Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-do...
20399994 - Pharmacokinetics of rosuvastatin in healthy chinese volunteers living in china: a rando...
2601564 - Tissue concentrations of mptp and mpp+ in relation to catecholamine depletion after the...
7872744 - Comparative efficacies of amphotericin b, triazoles, and combination of both as experim...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-09-15
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  50     ISSN:  1552-4604     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-21     Completed Date:  2010-03-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  101-8     Citation Subset:  IM    
Affiliation:
Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku and Turku University Hospital, Turku, Finland. juha.gronlund@utu.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Analgesics, Opioid / administration & dosage,  adverse effects,  pharmacokinetics*,  pharmacology*
Cytochrome P-450 CYP2D6 / antagonists & inhibitors,  genetics
Cytochrome P-450 CYP3A / antagonists & inhibitors
Drug Interactions
Female
Genotype
Humans
Ketolides / pharmacology*
Male
Oxycodone / administration & dosage,  adverse effects,  pharmacokinetics*,  pharmacology*
Pain Threshold / drug effects
Psychomotor Performance / drug effects*
Chemical
Reg. No./Substance:
0/Analgesics, Opioid; 0/Ketolides; 0/telithromycin; 76-42-6/Oxycodone; EC 1.14.13.67/CYP3A4 protein, human; EC 1.14.14.1/Cytochrome P-450 CYP2D6; EC 1.14.14.1/Cytochrome P-450 CYP3A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen spec...
Next Document:  Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Pa...